TWEAK as a target for therapy in systemic lupus erythematosus |
| |
Authors: | Rui-Xue?Leng Hai-Feng?Pan Wei-Zi?Qin Chao?Wang Li-Li?Chen Jin-Hui?Tao Email author" target="_blank">Dong-Qing?YeEmail author |
| |
Institution: | (1) Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, 230032 Hefei, Anhui, People’s Republic of China;(2) Department of Rheumatology, Anhui Provincial Hospital affiliated to Anhui Medical University, 17 Lujiang Road, 230001 Hefei, Anhui, People’s Republic of China; |
| |
Abstract: | Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a recently identified proinflammatory cytokine of the
TNF superfamily. Through activation of the fibroblast growth factor-inducible 14 (Fn14) receptor, TWEAK regulates cell proliferation,
cell death and inflammation. The available evidences have indicated that TWEAK might be a target for therapeutic intervention
in renal, vascular injury and neuropathy. Since renal, vascular and neuropsychiatric complications are frequently encountered
in systemic lupus erythematosus (SLE)—a systemic autoimmune disease, TWEAK-Fn14 pathway may be implicated in the pathogenesis
of SLE. In this review, we will discuss the TWEAK-Fn14 pathway and the therapeutic potential of modulating this pathway in
SLE. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|